Audeo Oncology (AURX) Files $60M IPO

July 6, 2012 4:21 PM EDT
Get Alerts AURX Hot Sheet
Trade AURX Now!
Join SI Premium – FREE
Audeo Oncology (Nasdaq: AURX) filed a $60 million IPO on form S-1 with the SEC after the close Friday. The company plans to list its common stock on The Nasdaq Global Market under the symbol "AURX."

Underwriters are Leerink Swann and Oppenheimer & Co.

Audeo Oncology is a late stage biopharmaceutical company primarily focused on utilizing our Hyaluronic Acid Chemotransport Technology, or HyACT, to target cancer drugs preferentially to tumor cells to enhance drug activity. HyACT is a flexible platform technology designed to increase the effectiveness of anti-cancer agents without increasing treatment toxicity. The company seek to reduce the risks related to drug development by using known anti-cancer drugs, and aim to enhance their commercial value by improving their effectiveness.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories


Related Entities


Add Your Comment